Skip to content
Inciteful Med

Biology and Types of Endocrine Tumors

Last updated:

Endocrine tumors develop in hormone-producing glands like the thyroid, pituitary, and pancreas. Even benign tumors can be serious if they produce excess hormones (functional tumors) or press on nearby organs. Doctors use markers like the Ki-67 index to determine how fast they grow.

Key Takeaways

  • • Endocrine tumors form in hormone-producing glands such as the pituitary, thyroid, parathyroid, adrenal glands, and pancreas.
  • • Even benign endocrine tumors can cause serious health issues by overproducing hormones or pressing on nearby organs.
  • • Functional tumors actively produce excess hormones, while non-functional tumors cause symptoms primarily through their physical size and location.
  • • The Ki-67 index on a pathology report indicates how fast the tumor cells are dividing, helping doctors understand its aggressiveness.
  • • Some endocrine tumors are linked to inherited genetic syndromes like MEN1 or VHL, which may prompt a recommendation for genetic testing.

The endocrine system is a complex network of glands that produce and release hormones—chemical messengers that travel through your bloodstream to control nearly every process in your body, from metabolism to growth [1][2]. When cells in these glands grow out of control, they form tumors. Endocrine tumors are unique because they don’t just take up space; they can also interfere with your body’s delicate chemical balance [3][4].

Major Glands Affected

Tumors can develop in several key glands throughout the body:

  • Pituitary Gland: Located at the base of the brain, it is often called the “master gland.” Tumors here are frequently called Pituitary Neuroendocrine Tumors (PitNETs) [5][6].
  • Thyroid Gland: Found in the front of the neck. Thyroid cancer is the most common malignant tumor of the endocrine system, with Papillary Thyroid Cancer being the most frequent type [7][8].
  • Parathyroid Glands: Four tiny glands behind the thyroid that regulate calcium. Tumors here can lead to high calcium levels in the blood [9][10].
  • Adrenal Glands: Sitting atop the kidneys, these glands produce adrenaline and cortisol. Tumors can occur in the outer layer (cortex) or the inner part (medulla) [11][12].
  • Pancreas (Neuroendocrine): While the pancreas also aids digestion, it contains endocrine cells that can develop into Pancreatic Neuroendocrine Tumors (pNETs), such as insulinomas or gastrinomas [3][13].

Benign vs. Malignant: A Different Perspective

In many cancers, “benign” means “harmless.” However, in the endocrine system, even a benign (non-cancerous) tumor can be serious due to two main factors:

1. Functional Status (Hormone Secretion)

A functional tumor produces excess hormones, which can cause severe symptoms [14][3]. For example, a functional pancreatic tumor (insulinoma) can cause dangerously low blood sugar, while a growth hormone-secreting pituitary tumor can cause body tissues to grow excessively (acromegaly) [1][2]. Non-functional tumors do not produce hormones but can still cause problems by growing [13][15].

2. Mass Effect

As a tumor grows, it can press on nearby organs, nerves, or blood vessels. This is known as mass effect [3][4]. A benign pituitary tumor, for instance, may press on the optic nerves, leading to vision loss, or cause persistent headaches [5][6].

How Endocrine Tumors Differ from Typical Cancers

Endocrine tumors, especially Neuroendocrine Neoplasms (NENs), behave differently than common carcinomas like lung or breast cancer:

  • Growth Rate: Many endocrine tumors are “well-differentiated” (NETs), meaning they look similar to healthy cells and grow very slowly over many years [16][17]. In contrast, “poorly differentiated” carcinomas (NECs) are much more aggressive [18][14].
  • Specific Markers: These tumors often produce specific proteins like Chromogranin A (CgA) or Synaptophysin, which doctors use as “markers” to identify them in blood tests or tissue samples [19][20].
  • Spread Patterns: When these tumors spread (metastasize), they often favor the liver rather than the lungs or bone, which is more common in other cancer types [21].
  • Grading (Ki-67): Doctors use a measurement called the Ki-67 index to determine how fast the tumor cells are dividing [22][23]. A lower Ki-67 usually indicates a slower-growing, less aggressive tumor [24].

Genetic Considerations

Sometimes, endocrine tumors are part of an inherited syndrome, such as Multiple Endocrine Neoplasia type 1 (MEN1) or Von Hippel-Lindau (VHL) syndrome [25][12]. These conditions can cause tumors to form in multiple glands at the same time [9][1]. If you have a family history of endocrine issues, your care team may suggest genetic counseling [26].

Frequently Asked Questions

What is the difference between a functional and non-functional endocrine tumor?
A functional tumor actively produces excess hormones, which can cause severe symptoms like sudden skin flushing, low blood sugar, or racing heart rate. A non-functional tumor does not produce hormones but can still cause problems by pressing on nearby organs as it grows.
What does the Ki-67 index mean on my pathology report?
The Ki-67 index is a measurement doctors use to see how fast your tumor cells are dividing. A lower Ki-67 score usually means the tumor is slow-growing and less aggressive, while a higher score indicates it is growing more quickly.
Are all endocrine tumors cancerous?
No, many endocrine tumors are benign, meaning they are not cancer. However, even benign endocrine tumors can be serious and require medical care if they overproduce hormones or press against important structures like optic nerves or blood vessels.
Why is my doctor checking my Chromogranin A levels?
Chromogranin A is a specific protein, or tumor marker, often produced by neuroendocrine tumors. Doctors monitor the levels of this protein in your blood to help identify the tumor and track its activity over time.
Are endocrine tumors hereditary?
While many occur randomly, some endocrine tumors are linked to inherited genetic conditions, such as Multiple Endocrine Neoplasia type 1 (MEN1) or Von Hippel-Lindau (VHL) syndrome. If you have a family history of these tumors, your doctor may recommend genetic counseling.

Questions for Your Doctor

  • • Which specific endocrine gland is the primary site of my tumor?
  • • Is my tumor 'functional' (producing hormones) or 'non-functional'?
  • • What is the 'grade' of my tumor, and what was the Ki-67 index on my pathology report?
  • • How does the location of this tumor affect nearby structures (mass effect)?
  • • Does my diagnosis suggest I should be tested for genetic syndromes like MEN1 or VHL?
  • • What specific tumor markers, like Chromogranin A, will we be monitoring?

Questions for You

  • • Have I noticed any 'functional' symptoms like sudden skin flushing, unexplained diarrhea, or racing heart rate?
  • • Am I experiencing any 'mass effect' symptoms, such as new headaches, vision changes, or a feeling of fullness in my abdomen?
  • • Do any of my close biological relatives have a history of endocrine tumors or rare genetic syndromes?
  • • How have my energy levels or mood changed since I first noticed symptoms?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.

    Chiloiro S, Capoluongo ED, Schinzari G, et al.

    Frontiers in endocrinology 2019; (10()):365 doi:10.3389/fendo.2019.00365.

    PMID: 31249555
  2. 2

    A Medically Managed Case of Acromegaly: A Case Report.

    Bdour K, Al-Sarihin K, El Issa N, et al.

    Cureus 2026; (18(1)):e101136 doi:10.7759/cureus.101136.

    PMID: 41664776
  3. 3

    Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report.

    Di Buono G, Bonventre G, Badalamenti G, et al.

    International journal of surgery case reports 2020; (77S()):S105-S108 doi:10.1016/j.ijscr.2020.09.120.

    PMID: 32981880
  4. 4

    Neuroendocrine Neoplasms.

    Kamboj S, Guerra-Bauman F, Mahmud H, Waheed A

    Primary care 2024; (51(3)):549-560 doi:10.1016/j.pop.2024.04.010.

    PMID: 39067978
  5. 5

    Clinical Biology of the Pituitary Adenoma.

    Melmed S, Kaiser UB, Lopes MB, et al.

    Endocrine reviews 2022; (43(6)):1003-1037 doi:10.1210/endrev/bnac010.

    PMID: 35395078
  6. 6

    Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.

    Tsukamoto T, Miki Y

    Japanese journal of radiology 2023; (41(8)):789-806 doi:10.1007/s11604-023-01400-7.

    PMID: 36826759
  7. 7

    [Modern aspects influencing the management of patients with papillary thyroid cancer].

    Skibitskaya MV, Kuznetsov NS

    Khirurgiia 2023; 89-94 doi:10.17116/hirurgia202312189.

    PMID: 38088845
  8. 8

    Thyroid carcinoma with atypical metastasis to the pituitary gland and unexpected postmortal diagnosis.

    Popławska-Kita A, Wielogórska M, Poplawski Ł, et al.

    Endocrinology, diabetes & metabolism case reports 2020; (2020()).

    PMID: 32168468
  9. 9

    Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of 18F-Fluorocholine PET/CT in MEN1 Syndrome.

    Arora S, Damle NA, Passah A, et al.

    Nuclear medicine and molecular imaging 2018; (52(3)):238-242 doi:10.1007/s13139-018-0520-2.

    PMID: 29942404
  10. 10

    The Role of Lithium in Management of Endocrine Tumors-A Comprehensive Review.

    Thakur S, Tobey A, Klubo-Gwiezdzinska J

    Frontiers in oncology 2019; (9()):1092 doi:10.3389/fonc.2019.01092.

    PMID: 31750236
  11. 11

    Spontaneous lesions in endocrine glands of experimental Wistar rats and beagle dogs.

    Nataraju GJ, Ranvir RK, Kothule VR, et al.

    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 2016; (68(1)):1-13.

    PMID: 26414849
  12. 12

    Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

    Chevalier B, Dupuis H, Jannin A, et al.

    Frontiers in endocrinology 2021; (12()):678869 doi:10.3389/fendo.2021.678869.

    PMID: 34025587
  13. 13

    The future: surgical advances in MEN1 therapeutic approaches and management strategies.

    Sadowski SM, Cadiot G, Dansin E, et al.

    Endocrine-related cancer 2017; (24(10)):T243-T260 doi:10.1530/ERC-17-0285.

    PMID: 28811298
  14. 14

    Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.

    Guilmette JM, Nosé V

    Advances in anatomic pathology 2019; (26(1)):13-30 doi:10.1097/PAP.0000000000000201.

    PMID: 29912000
  15. 15

    A germline c.1546dupC MEN1 mutation in an MEN1 family: A case report.

    Cho YY, Chung YJ

    Medicine 2021; (100(25)):e26382 doi:10.1097/MD.0000000000026382.

    PMID: 34160414
  16. 16

    Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.

    Kole C, Charalampakis N, Vailas M, et al.

    Cancer immunology, immunotherapy : CII 2022; (71(4)):761-768 doi:10.1007/s00262-021-03046-8.

    PMID: 34471940
  17. 17

    Primary Mesenteric Carcinoid Tumor Presenting with Carcinoid Syndrome.

    Shogbesan O, Abdulkareem A, Pappachen B, Altomare J

    Case reports in gastroenterology 2018; (12(2)):396-401 doi:10.1159/000490522.

    PMID: 30186091
  18. 18

    Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.

    Kasajima A, Perren A, Klöppel G

    Virchows Archiv : an international journal of pathology 2026; (488(1)):3-20 doi:10.1007/s00428-025-04296-y.

    PMID: 41483302
  19. 19

    Chromogranin A - unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls.

    Gut P, Czarnywojtek A, Fischbach J, et al.

    Archives of medical science : AMS 2016; (12(1)):1-9 doi:10.5114/aoms.2016.57577.

    PMID: 26925113
  20. 20

    [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].

    Klöppel G

    Der Pathologe 2019; (40(3)):211-219 doi:10.1007/s00292-019-0594-3.

    PMID: 30969346
  21. 21

    Comparison of Metastatic Patterns Among Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Nonneuroendocrine Carcinomas of Various Primary Organs.

    Park HK, Kwon GY

    Journal of Korean medical science 2023; (38(11)):e85 doi:10.3346/jkms.2023.38.e85.

    PMID: 36942393
  22. 22

    Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

    Mete O, Wenig BM

    Head and neck pathology 2022; (16(1)):123-142 doi:10.1007/s12105-022-01435-8.

    PMID: 35312985
  23. 23

    Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

    Coriat R, Walter T, Terris B, et al.

    The oncologist 2016; (21(10)):1191-1199 doi:10.1634/theoncologist.2015-0476.

    PMID: 27401895
  24. 24

    Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms.

    Shi H, Chen L, Zhang Q, et al.

    Pancreas 2020; (49(10)):1378-1382 doi:10.1097/MPA.0000000000001693.

    PMID: 33122528
  25. 25

    [Multiple endocrine neoplasia type 1: about a case].

    Anguezomo G, El Mghari G, El Ansari N

    The Pan African medical journal 2019; (33()):238 doi:10.11604/pamj.2019.33.238.18053.

    PMID: 31692695
  26. 26

    MEN1 in a Patient With Nonsyndromic Familial Nonmedullary Thyroid Carcinoma.

    Fitzgerald LA, Williamson S, Shakil J, Robbins RJ

    JCEM case reports 2023; (1(1)):luac019 doi:10.1210/jcemcr/luac019.

    PMID: 37908266

This page provides educational information about the biology and types of endocrine tumors. It does not replace professional medical advice. Always discuss your specific tumor type, pathology report, and symptoms with your endocrinologist or oncologist.

Stay up to date

Get notified when new research about Tumor of endocrine glands is published.

No spam. Unsubscribe anytime.